Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics
A MARIE SKŁODOWSKA-CURIE ACTIONS (MSCA) Innovative Training Network (ITN)
An estimated 240,000 cases of brain and nervous system tumours are diagnosed every year, worldwide and Glioblastoma (GBM) is the most frequent and aggressive brain tumour. New treatment options and effective precision medicine therapies are urgently required. GLIOTRAIN is a multi-sectoral industry-academia collaboration, funded by the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie ITN initiative, that will work to identify novel strategies to treat GBM as well as investigating resistance mechanisms in this devastating disease.
The GLIOTRAIN consortium are pleased to announce that we will be hosting a satellite pre-meeting at this years’ European Society of Neuro-Oncology (EANO) annual meeting. EANO is scheduled to take place in Glasgow, UK 10 – 13 September and the GLIOTRAIN pre-meeting will take place on the 9 September.
On October 25th 2019, the Physiology Dept of the Royal College of Surgeons organised a symposium and raffle to raise awareness surrounding brain tumour diagnosis and to raise vital funds for local charity, Brain Tumour Ireland.
The 2nd GLIOTRAIN annual meeting took place at the Institute for Cell Biology and Immunology at the University of Stuttgart on the 7th and 8th October 2019. The consortium took the opportunity to discuss key issues and all of the ESRs presented updates on their work.
